[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366559-105":59,"doc-detail-366559-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unlocking-new-frontiers-novel-immune-targets-for-next-generation-cancer-immunotherapy","Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy","","Cancer immunotherapy uses the body’s immune system to recognize and eliminate malignant cells with greater specificity than conventional tumor-directed treatments. While immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have advanced clinical care, progress is constrained by resistance, patient-to-patient response heterogeneity, and limited efficacy across tumor types. This review synthesizes current research aimed at identifying and validating novel immune targets, including emerging checkpoints and co-stimulatory pathways, to improve synergy with existing therapies or enable independent anti-tumor activity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unlocking-new-frontiers-novel-immune-targets-for-next-generation-cancer-immunotherapy/366559/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unlocking-new-frontiers-novel-immune-targets-for-next-generation-cancer-immunotherapy/366559.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is there a need to find novel immune targets for cancer immunotherapy?","Question",{"text":112,"@type":113},"Current ICIs are limited by resistance mechanisms, heterogeneous patient responses, and insufficient efficacy across tumor types. Novel targets are sought to complement existing treatments or work independently to improve outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which major pathways do immune checkpoint inhibitors primarily target?",{"text":117,"@type":113},"The review highlights ICIs that target PD-1/PD-L1 and CTLA-4 pathways as major breakthroughs in the field.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the difference between emerging immune checkpoints and co-stimulatory molecules?",{"text":121,"@type":113},"Emerging immune checkpoints are inhibitory receptors that regulate immune responses and can contribute to tumor immune evasion. Co-stimulatory molecules promote T-cell activation and enhance anti-tumor immunity when engaged.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366559,1790463686,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Korean Journal of Clinical Oncology 2025;21:47-80 [https://doi.org/10.14216/kjco.24322](https://doi.org/10.14216/kjco.24322)[ ](https://doi.org/10.14216/kjco.24322)[pISSN 1738-8082](pISSN 1738-8082) ∙ eISSN 2288-4084  \nReview  \nUnlocking new frontiers: novel immune targets for next-generation cancer immunotherapy  \nSufian Zaheer, Niti Sureka  \nDepartment of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India  \nCancer immunotherapy represents a transformative strategy in modern oncology, utilizing the body’s immune system to recognize and eliminate malignant cells with precision. Unlike traditional therapies, which often directly target the tumor, immunotherapy enhances the immune system’s inherent ability to differentiate between healthy and cancerous cells. The advent of immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 and CTLA-4 pathways, has marked a significant breakthrough in this field. However, the therapeutic landscape is still challenged by issues such as the development of resistance mechanisms, heterogeneity in patient responses, and the limited efficacy of current ICIs across all tumor types. Given these challenges, there is a critical need to identify and validate new immune targets that can synergize with existing therapies or function independently to overcome resistance and improve patient outcomes. This review provides a comprehensive overview of the latest research efforts focused on uncovering novel immune targets. By expanding the repertoire of immune targets, these discoveries aim to enhance the effectiveness of cancer immunotherapy, offering hope for more personalized and resilient treatment options. The integration of these novel targets into clinical practice could not only extend the benefits of immunotherapy to a broader spectrum of cancers but also mitigate some of the current limitations, paving the way for more durable and effective therapeutic strategies in the fight against cancer.  \nKeywords: Immunotherapy, Immune checkpoints, TAM receptors, CD73, Adenosine pathway  \nINTRODUCTION  \nCancer immunotherapy represents a groundbreaking strategy in contemporary oncology, utilizing the body’s immune system to target and eliminate malignant cells. Unlike traditional treatments that directly target tumors, immunotherapy aims to stimulate or enhance the immune system’s ability to recognize and eliminate cancer cells, offering the potential for more durable and targeted therapeutic outcomes [1]. Immunotherapy, including adoptive cell transfer and immune checkpoint inhibitors (ICIs), is a cancer treatment that harnesses the power of the immune system to target and eliminate tumor cells. Used either on its own or alongside traditional treatments such as radiotherapy and chemotherapy, this  \nReceived: Nov 21, 2024 Revised: May 31, 2025 Accepted: Jun 4, 2025  \nCorrespondence to: Sufian Zaheer  \nDepartment of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, Ring Road, New Delhi 110029, India  \nTel: +91-9650594818, Fax: +91-9650594818  \n[E-mail:](E-mail: sufianzaheer@gmail.com)[ sufianzaheer@gmail.com](E-mail: sufianzaheer@gmail.com)[ ](E-mail: sufianzaheer@gmail.com)© 2025 Korean Society of Surgical Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/4.0](http://creativecommons.org/licenses/by-nc/4.0)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \napproach has become a standard and highly successful option for treating many cancers [2]. Notably, ICIs that target PD-1/PD-L1 and CTLA-4 have gained prominence in clinical practice [2] . These therapies have achieved significant success by effectively releasing the brakes on the immune response, allowing the immune system to detect and attack tumors that previously evade","cbCaijsKcKfQ3Jxh","https://ap.wps.com/l/cbCaijsKcKfQ3Jxh","pdf",3058497,34,"English","# Introduction\n# Emerging immune checkpoints\n# Novel co-stimulatory molecules\n# Review scope and advancements","[{\"question\":\"Why is there a need to find novel immune targets for cancer immunotherapy?\",\"answer\":\"Current ICIs are limited by resistance mechanisms, heterogeneous patient responses, and insufficient efficacy across tumor types. Novel targets are sought to complement existing treatments or work independently to improve outcomes.\"},{\"question\":\"Which major pathways do immune checkpoint inhibitors primarily target?\",\"answer\":\"The review highlights ICIs that target PD-1/PD-L1 and CTLA-4 pathways as major breakthroughs in the field.\"},{\"question\":\"What is the difference between emerging immune checkpoints and co-stimulatory molecules?\",\"answer\":\"Emerging immune checkpoints are inhibitory receptors that regulate immune responses and can contribute to tumor immune evasion. Co-stimulatory molecules promote T-cell activation and enhance anti-tumor immunity when engaged.\"}]","Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy | PDF",1790166079,86,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30475618382806ccdaf88d5309445dae.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c92d33425ad8a9d739e4643b4f0429dc.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/433b8bb80688066dac987fb5bd190f54.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e8bdad48d7afdb45778c3e930c17a75.webp",980,1306]